cas 854515-52-9|| where to buy 6-hydroxy-2-methylbenzofuran-3-carboxylic acid

製品名:6-hydroxy-2-methylbenzofuran-3-carboxylic acid

IUPAC Name:6-hydroxy-2-methyl-1-benzofuran-3-carboxylic acid

包装単位	有効在庫	価格（USD）
CM132795-100mg	in stock	ƻƅƏ
CM132795-250mg	in stock	ŭƏǠ
CM132795-1g	in stock	şŭŭ
CM132795-5g	in stock	ŭşȋş

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 854515-52-9 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:854515-52-9; 分子式:C10H8O4; 融点:-; SMILESコード:CC1=C(C(O)=O)C2=C(O1)C=C(O)C=C2; 密度:

: カタログ番号:CM132795; 分子量:192.17; 沸点:235.838°C at 760 mmHg; MDL番号:MFCD12547297; 保管方法:Store at 2-8°C.

: Benzofurans; Benzofuran is an aromatic heterocyclic organic compound with the chemical formula C8H6O. It is a colorless oily liquid at room temperature with an aromatic odor. Benzofuran can be volatilized with water vapor and can be decomposed by potassium permanganate and other oxidants. It is an intermediate for the preparation of amiodarone and indene resin. Benzofuran derivatives are important pharmaceutical intermediates.; Benzofuran | C8H6O | CID 9223 -Chemenu; Benzofuran | C8H6O | CID 9223 |Where to Buy Benzofurans; Benzofuran is the heterocyclic compound consisting of fused benzene and furan rings. This colourless liquid is a component of coal tar.Benzofuran is extracted from coal tar. It is also obtained by dehydrogenation of 2-ethylphenol.

: Fruquintinib; November 08, 2023, FDA has approved FRUZAQLA(fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
FRUZAQLA is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.